ClinicalTrials.gg
RecruitingNCT06187155Updated Sep 5, 2024

Impact of Education Level on Clinical Outcomes in Self-INR Managed Patients

An interventional study of INR self-management in Atrial Fibrillation and Flutter and Mechanical Mitral Valve Prosthesis, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-05.

Sponsored by Cairo University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
586
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Atrial Fibrillation with a site in Egypt — 9 open to participants now, 12 under way, 1 of them phase 3. Atrial Fibrillation · Egypt.

Planned enrollment
5th of 21
586 · median 180
Started
2023
with 1 other
No phase
8 of 33
2 open now
Primary completion
2024-12
later than 4 of 11 live
Registered
24th of 33
by date
Lead sponsor
1 of 33
Cairo University

Among the 33 studies in Atrial Fibrillation with a site in Egypt, this one is the 5th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2023, is one of 8 with no phase, reaches primary completion later than 4 of the 11 other live ones, and was the 24th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

9 of the 33 studies in Atrial Fibrillation with a site in Egypt are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Atrial Fibrillation with a site in Egypt, or all of them as a file.
02

Study summary

Oral anticoagulation (OAC) is indicated in a wide variety of clinical conditions including atrial fibrillation (AF), mechanical valve prosthesis (MVP), deep vein thrombosis and pulmonary embolism. Although direct OAC has replaced vitamin K antagonists (VKA) in non-valvular AF due to lower bleeding risk, it's still recommended to use VKA specifically in cases of valvular AF, MVP and anti-phospholipid syndrome.

VKA has a narrow therapeutic range and multiple drug interactions causing unpredicted pharmacodynamics. This requires regular monitoring of the international normalized ratio (INR) level to ensure it's in the target therapeutic range and prevent extreme values that may result in thrombo-embolic events or sometimes fatal bleeding.

Self-INR monitoring and management have emerged recently as a safe cost-effective alternative to standard management, with evidence of tighter control of INR, reduction of thrombo-embolic events, and improving treatment-related quality of life. However, there are no specific criteria for patient selection. Whether the level of education and other social factors would affect the outcomes of self-management is still not clear.

Owing to the wide geographical area served by Aswan Heart Center, many patients have to cover long distances to follow up their INR and seek medical advice regarding adequate dose modification. This may result in reluctance and non-compliance to clinic visits and INR testing. Proper education, training and providing an alternative near place to measure the INR and self-adjust warfarin dose is expected to improve patient adherence and compliance.

Read the detailed description

Study Methods

  • Population of study: Patients who have a clinical indication for long term VKA.
  • Study location: Aswan Heart Center.
  • Inclusion criteria: Adult patients above 18 years who are indicated for long term VKA and has been on VKA for more than 6 months.
  • Exclusion criteria:

    1. Refusal to join the study. 2. History of life-threatening bleeding or thrombo-embolic events. 3. Illiterate patients with no caregivers living at the same home.
  • Patient informed consent:

Individual informed consent will be taken from every candidate for the study. The candidates will have the right to withdraw from the study at any time without any changes in the clinical service provided to them.

  • Methodology in details:

A-Medical history including:

Age, gender, indication of VKA. Data about valve surgery including date, location and type of valve. Past history of any chronic medical conditions, thrombo-embolic or bleeding events. Past history of blood transfusion.

B-Social history including:

Marital status, occupation, level of education and self-care capability.

C- Clinical examination including:

Assessment of body weight, height and body mass index calculation. Vital signs including blood pressure measurement using standard technique, assessment of the pulse, respiratory rate and temperature.

C- Blood sample and chemistry:

Blood tests will be done for all participants initially and at the end of the study. Laboratory workup will include complete blood count, liver, kidney function tests and electrolytes.

F- Electrocardiography (ECG):

12-lead ECG will be done for all participants initially and the end of the study to confirm rhythm.

H- Echocardiography:

  • Trans-thoracic echocardiography will be done for all patients to assess valve function, leaflet excursion, peak and mean pressure gradients across the valve.
  • In case of abnormally elevated pressure gradients, abnormal leaflet motion or suspected prosthesis-related mass, trans-oesophageal echocardiography will be done to confirm or exclude MVP malfunction.

I. Randomization:

  • Patients will be randomized with the ratio of 1:1 to undergo self-management of INR versus standard management in the anticoagulation clinic using a randomization table.
  • Self-management arm:

    • All participants will receive full education class of minimum one-hour time and training about how to interpret INR levels and adjust their medication dose according to a pre-determined dose-INR schedule.
    • A registered nurse will be responsible for education and training. Another registered nurse would be responsible to check the participant feedback and well-understanding.
    • The participant will receive a chart to record INR results, test dates and dose modifications for the upcoming 6 months.
    • The participant will be educated about bleeding events, how to grade and when to seek medical attention immediately.
    • The participant will be educated about early manifestations of thrombo-embolism including shortness of breath, focal neurological deficits or lower limb pain.
    • If INR exceeds 8 at any time, the participant will be instructed to urgently contact the center and seek medical advice, he/she will be withdrawn from the trial and switched to the standard monitoring care.
    • If major bleeding or thrombotic event occurred, the participant will be instructed to contact us urgently and will be withdrawn from the trial and switched to the standard monitoring care.
  • Standard monitoring arm:

    • This group will be managed according to the local protocol of INR monitoring in a dedicated anticoagulation clinic. A registered nurse (supervised by a physician) would be responsible for medication dose adjustment, scheduling tests and recording any thrombo-embolic or bleeding events.

K. Follow-up:

Standard monitoring group will be reviewed on monthly basis or less according to INR test results. Self-management group will be reviewed 6 months after randomization, with the following data to be obtained:

  1. All-cause death.
  2. Bleeding events will be graded according to BARC classification

    • Minor bleeding Type 1: self-controlled bleeding that doesn't need seeking medical advice.
    • Major bleeding Type 2: Overt bleeding that requires medical intervention or hospitalization. Type 3a: Bleeding with Hb drop (3-5 gm/dL), or requiring blood transfusion. Type 3b: Bleeding with Hb drop 5 gm/dL or more, or requiring surgical intervention.

Type 4: Coronary artery bypass graft-related bleeding. Type 5: Fatal bleeding. 4. Thrombo-embolic event: defined as mechanical valve thrombosis confirmed by trans-oesophageal echocardiography (prosthesis-related mass, elevated gradients, stuck leaflet motion), cerebrovascular stroke, peripheral embolism causing acute limb ischemia.

  1. Time and proportion of tests in therapeutic range will be calculated using Rosendaal method.
  1. Frequency of tests will be recorded.

In case of mortality, data will be collected about the date and cause of mortality, and any reported clinical events before mortality.

Data will be presented and used without inference to the name or personal data of the patients. All patient records will be handled in accordance to hospital and national confidentiality protocols.

03

Conditions studied

  • Atrial Fibrillation and Flutter
  • Mechanical Mitral Valve Prosthesis

Browse trials for

Keywords

  • INR self-management
  • education level
  • warfarin
  • time in therapeutic range
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients above 18 years who are indicated for long term VKA and has been on VKA for more than 6 months.

Exclusion criteria

Exclusion Criteria:

  1. Refusal to join the study.
  2. History of prior life-threatening bleeding or thrombo-embolic events.
  3. Illiterate patients with no caregivers living at the same home.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
586 participants (estimated)

Study arms

  • Experimental
    INR-self management

    The participants will be responsible to monitor their INR regularly and adjust the warfarin dose by themselves accordingly, without seeking medical advice from medical personnel for 6 months. All participants will receive full education class of minimum one-hour time and training about how to interpret INR levels and adjust their medication dose according to a pre-determined dose-INR schedule.

    Other: INR self-management

  • No intervention
    Standard of care

    Regular INR monitoring and seeking medical advice at Aswan Heart Centre

Interventions

  • OtherINR self-management

    will receive full education class of minimum one-hour time and training about how to interpret INR levels independently and adjust their medication dose according to a pre-determined dose-INR schedule.

06

What researchers measure

Primary outcomes

  1. Time and proportion of INR in therapeutic range

    Time in therapeutic range and percentage of test results in therapeutic range

    Time frame: 6 months

Secondary outcomes

  1. All-cause mortality

    Death from any cause

    Time frame: 6 months

  2. Thrombo-embolic events

    Stroke, valve thrombosis or peripheral embolism

    Time frame: 6 months

  3. Major bleeding

    Overt bleeding that requires medical intervention or hospitalization

    Time frame: 6 months

  4. Minor bleeding

    Self-controlled bleeding that doesn't need seeking medical advice

    Time frame: 6 months

  5. Frequency of testing

    Number of tests per specific time range

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Informed consent form, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2024, 12 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 12 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2023
First posted
Jan 2, 2024
StartActual
Dec 1, 2023
Primary completionEst.
Dec 1, 2024
CompletionEst.
Dec 1, 2024
Last update
Sep 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06187155
Lead sponsor
Cairo University
Collaborators
Magdi Yacoub Heart Foundation
Responsible party
Hossameldin Elsayed Khalifa Hussein (Associate Specialist of Adult Cardiology, Magdi Yacoub Heart Foundation) — Principal investigator
First posted
Jan 2, 2024
Start date
Dec 1, 2023
Primary completion
Dec 1, 2024 (estimated)
Completion
Dec 1, 2024 (estimated)
Last update
Sep 5, 2024

Study contacts

Hossameldin Hussein, MSc
Contact
hossameldin_hussein@kasralainy.edu.eg
+201092565995
Mohamed Hosny, MD
study director · Aswan Heart Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion